cysteamine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, HA; Mangla, JC; Pihan, G; Rattan, S; Szabo, S | 1 |
| Cho, CH; Szabo, S | 1 |
| Kline, TJ; Pihan, G; Szabo, S | 1 |
| Neumeyer, JL; Szabo, S | 1 |
| Hasegawa, E; Murai, Y; Oishi, T | 1 |
| Szabo, S | 1 |
| Ahn, EH; Cho, SW; Choi, SY; Eum, WS; Hwang, JH; Jeong, HJ; Kang, HW; Kang, TC; Kim, DS; Kim, DW; Kim, MJ; Kwon, OS; Lee, YP; Park, J; Shin, MJ; Sohn, EJ | 1 |
| Choi, SY; Choi, YJ; Eum, WS; Han, KH; Kim, DS; Kim, DW; Lee, KW; Lee, LR; Park, J; Park, JK; Shin, MJ; Song, Y; Yeo, EJ; Yeo, HJ | 1 |
| Li, Q; Quan, J; Wang, X; Xu, B; Xu, Z | 1 |
1 review(s) available for cysteamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
From cysteamine to MPTP: structure-activity studies with duodenal ulcerogens.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cysteamine; Duodenal Ulcer; Pyridines; Rodentia; Structure-Activity Relationship | 1988 |
8 other study(ies) available for cysteamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Effect of duodenal ulcerogens cysteamine, mepirizole, and MPTP on duodenal myoelectric activity in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cysteamine; Duodenal Ulcer; Duodenum; Epirizole; Female; Gastrointestinal Motility; Pyrazoles; Pyridines; Rats; Rats, Inbred Strains | 1989 |
Biphasic effect of duodenal ulcerogens on gastric emptying in the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chronic Disease; Cysteamine; Drug Administration Schedule; Duodenal Ulcer; Epirizole; Female; Gastric Emptying; Injections, Subcutaneous; Pyrazoles; Pyridines; Rats; Rats, Inbred Strains; Time Factors | 1988 |
Evidence for the involvement of dopamine agonists and antagonists in duodenal ulcer disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Brain Chemistry; Cysteamine; Dopamine; Duodenal Ulcer; Gastric Juice; Monoamine Oxidase; Nitriles; Norepinephrine; Pancreatic Juice; Pyridines; Receptors, Dopamine; Secretory Rate; Serotonin; Structure-Activity Relationship | 1986 |
Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Cysteamine; Dimercaprol; Dopamine; Dopamine Agents; Glutathione; Homovanillic Acid; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Nerve Degeneration; Nervous System Diseases; Pyridinium Compounds; Sulfhydryl Compounds | 1993 |
Hans Selye and the development of the stress concept. Special reference to gastroduodenal ulcerogenesis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Glands; Cysteamine; History, 20th Century; Humans; Neurosecretory Systems; Peptic Ulcer; Stress, Physiological; Stress, Psychological | 1998 |
PEP-1-heat shock protein 27 protects from neuronal damage in cells and in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Death; Cell Line, Tumor; Cysteamine; DNA Fragmentation; Dopaminergic Neurons; Escherichia coli; HSP27 Heat-Shock Proteins; Humans; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Parkinson Disease, Secondary; Peptides; Reactive Oxygen Species; Recombinant Fusion Proteins; Rotarod Performance Test; Substantia Nigra | 2012 |
PEP-1-GLRX1 Reduces Dopaminergic Neuronal Cell Loss by Modulating MAPK and Apoptosis Signaling in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cell Line; Cysteamine; Disease Models, Animal; Dopaminergic Neurons; Gene Expression Regulation; Glutaredoxins; Humans; Male; MAP Kinase Signaling System; Mice; Parkinson Disease; Peptides; Substantia Nigra | 2021 |
N-cystaminylbiguanide MC001 prevents neuron cell death and alleviates motor deficits in the MPTP-model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cysteamine; Disease Models, Animal; Dopaminergic Neurons; Glutamate-Cysteine Ligase; Mice; Mice, Inbred C57BL; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Substantia Nigra | 2022 |